Get all your news in one place.
100's of premium titles.
One app.
Start reading
Evening Standard
Evening Standard
Business
Henry Saker-Clark

FORGOTTEN HISTORY: Haleon shares slide after targets cut due to weak cold and flu demand | History Defined

Haleon floated on the London Stock Exchange with a value of more than £30 billion (Haleon/PA) -

Consumer healthcare firm Haleon has cut its sales targets for the year after being knocked by weaker demand for cold and flu medicine.

Shares in the Panadol and Sensodyne owner slumped in early trading as it also highlighted an impact from import changes in China.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.